Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmaron Beijing CoFRA:17Q1 -2.52%74 5-Year Yield-on-Cost % is 2.16 as of Sep. 09, 2026, which is 32% above its 10-year median of 1.64. GuruFocus rates FRA:17Q1 with a GF Score™ of 74/100 and a GF Value™ of €2.54 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 148 Biotechnology companies, Pharmaron Beijing Co ranks worse than 56.08% on this metric.
Pharmaron Beijing Co's yield on cost for the quarter that ended in Jun. 2026 was 2.16.
The historical rank and industry rank for Pharmaron Beijing Co's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:17Q1'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.18 Med: 1.64 Max: 6.95
Current: 2.16
During the past 12 years, Pharmaron Beijing Co's highest Yield on Cost was 6.95. The lowest was 0.18. And the median was 1.64.
FRA:17Q1's 5-Year Yield-on-Cost % is ranked worse than 56.08% of 148
companies
in the Biotechnology industry
Industry Median: 1.615
vs FRA:17Q1: 2.16
Pharmaron Beijing Co (FRA:17Q1) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Pharmaron Beijing Co 5-Year Yield-on-Cost % Related Terms
FRA:17Q1 vs VRTX, REGN, MRNA: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Pharmaron Beijing Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaron Beijing Co 5-Year Yield-on-Cost % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Pharmaron Beijing Co's 5-Year Yield-on-Cost % falls into.
Pharmaron Beijing Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Pharmaron Beijing Co (FRA:17Q1) has a 5-Year Yield-on-Cost % of 2.16 as of Sep. 09, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pharmaron Beijing Co and its competitors. This is 32% above median its historical median of 1.64. Over the past decade, Pharmaron Beijing Co's 5-Year Yield-on-Cost % has ranged from 0.18 to 6.95. According to the industry distribution chart, Pharmaron Beijing Co ranks #83 out of 148 companies in the Biotechnology industry, placing it in the top 56.1%.
Is Pharmaron Beijing Co's 5-Year Yield-on-Cost % too high?
Pharmaron Beijing Co's current 5-Year Yield-on-Cost % of 2.16 is 32% above median its 10-year median of 1.64. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 6.95. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.62. Pharmaron Beijing Co's value of 2.16 is 33.7% above this industry median. Based on the distribution chart, Pharmaron Beijing Co ranks #83 out of 148 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Pharmaron Beijing Co has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmaron Beijing Co ranks #83 out of 148 companies for 5-Year Yield-on-Cost %. This places Pharmaron Beijing Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.62. Pharmaron Beijing Co's value of 2.16 is 33.7% above this benchmark. Historically, Pharmaron Beijing Co's own 5-Year Yield-on-Cost % has ranged from 0.18 to 6.95 over the past decade. While the company's 10-year median is 1.64 vs. the industry median of 1.62, Pharmaron Beijing Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.62, based on 148 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmaron Beijing Co's current 5-Year Yield-on-Cost % of 2.16 is 33.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Pharmaron Beijing Co and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmaron Beijing Co's current 5-Year Yield-on-Cost % is 2.16, which is 32% above median its own 10-year median of 1.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Based on GuruFocus' analysis, Pharmaron Beijing Co (FRA:17Q1) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.54, compared to a current price of €3.10 — trading 22% above its estimated fair value. The current 5-Year Yield-on-Cost % is 2.16, which is 32% above median its 10-year median of 1.64 and 33.7% above the Biotechnology industry median of 1.62. Pharmaron Beijing Co's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Pharmaron Beijing Co (FRA:17Q1), the current 5-Year Yield-on-Cost % is 2.16 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (FRA:17Q1) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of €3.10 is trading 22% above its estimated GF Value™ of €2.54.
GuruFocus considers Pharmaron Beijing Co to be Modestly Overvalued.
Key valuation signals for FRA:17Q1:
5-Year Yield-on-Cost %: 2.16 (32% above median its 10-year median of 1.64)
GF Value™: €2.54 vs. price of €3.10 (22% above fair value)
Industry Position: 33.7% above the Biotechnology median (#83 of 148)
No single metric tells the full story. See the FRA:17Q1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
74GF Score
Get the complete analysis for FRA:17Q1
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:17Q1 has been successfully added to your 
